Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563789 | 0.90 | GAA (0.60) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL433268 | 0.87 | CYP3A4 (0.59) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL1645875 | 0.86 | VCAM1 (0.48) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL6244176 | 0.85 | ALDH1A1 (0.55) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL11526155 | 0.84 | ALDH1A1 (0.51) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL10767584 | 0.82 | ALDH1A1 (0.51) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL10438569 | 0.82 | TDP1 (0.51) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL27527075 | 0.82 | TDP1 (0.51) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL27527076 | 0.82 | TDP1 (0.51) | ALDH1A1TDP1CYP3A4TSHRHTT | |
| SCHEMBL12929973 | 0.81 | ALDH1A1 (0.62) | ALDH1A1TDP1CYP3A4TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117247515-A | Polyimide containing Trringer's Base element and gas separation membrane and method prepared by polyimide | 西北工业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-116854913-A | Preparation method of high-impact-resistance bismaleimide resin | 西北工业大学 | 2023-10-10 | — | — | CN | claimed |
| EP-0292911-A2 | Process for the preparation of pure nitro-aminobenzene-compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-30 | — | — | EP | claimed |
| CN-117247515-A | Polyimide containing Trringer's Base element and gas separation membrane and method prepared by polyimide | 西北工业大学 | 2023-12-19 | — | — | CN | disclosed |
| CN-116854913-A | Preparation method of high-impact-resistance bismaleimide resin | 西北工业大学 | 2023-10-10 | — | — | CN | disclosed |
| CN-116375760-A | Diamine containing DDSQ element and polyimide gas separation membrane prepared from diamine and method | 西北工业大学 | 2023-07-04 | — | — | CN | disclosed |
| EP-2097413-B1 | 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| CN-101679410-B | 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD | 2013-11-27 | — | — | CN | disclosed |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | F2G LTD (GB) | 2011-07-28 | — | — | US | disclosed |
| CN-102105170-A | Antifungal combination therapy | F2G LTD | 2011-06-22 | — | — | CN | disclosed |
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | DIXON BRIAN R (US) | 2003-11-06 | — | — | US | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6353006-B1 | TREATMENT OF BONE DISORDERS, OSTEOPOROSIS AND HEALING AGENT | BAYER CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-1144396-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | Bayer Corporation (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042031-A2 | SUBSTITUTED 2-ARYLIMINO HETEROCYCLES AND COMPOSITIONS CONTAINING THEM, FOR USE AS PROGESTERONE RECEPTOR BINDING AGENTS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| US-5387295-A | Cellulose, nitroglycerin, hydroxy-terminated prepolymer, isocyanate cross-linking agent; storage stability | HERCULES INCORPORATED (US) | 1995-02-07 | — | — | US | disclosed |
| EP-0362725-A1 | Process for producing water insoluble azo dyes on the fibre according to the ice-colour technique | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-04-11 | — | — | EP | disclosed |
| US-4801717-A | PLANT GROWTH REGULATORS | ROUSSEL UCLAF (FR) | 1989-01-31 | — | — | US | disclosed |
| EP-0292911-A2 | Process for the preparation of pure nitro-aminobenzene-compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207865-A1 | Substituted 2-arylimino heterocycles and compositions containing them for use as progesterone receptor binding agents | PGR, PGRMC2, PGRMC1 | ALDH1A1 587/4885TDP1 3939/4885CYP3A4 199/4885 |
| US-20110183969-A1 | ANTIFUNGAL COMBINATION THERAPY | IDO1, FOXM1, IPO5 | ALDH1A1 2813/4885TDP1 2131/4885CYP3A4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.